Gessel has advised Medicalgorithmics on its approximately PLN 220 million sale of a 49.99% stake in the company to investor Biofund.
According to a Medicalgorithmics press release, “an investment agreement was signed between Medicalgorithmics and Biofund Capital Management, based in Miami, to acquire 4.976.384 new shares in the company, up to 49.99% general meeting votes, which Biofund will acquire for a contribution of approximately PLN 220 million. The issue price will be PLN 44.27 per share.”
Medicalgorithmics is a Polish company that develops diagnostic systems for cardiology. Biofund is a US-based investment company.
The Gessel team was led by Partner Karol Sokol and Associate Dominik Kaszuba and included Partner Bernadeta Kasztelan-Swietlik, Managing Associate Magdalena Szeplik, and Associate Maciej Kowalski.
Gessel did not respond to our inquiry on the matter.